Suppression of androgen receptor (AR) signaling remains a therapeutic goal for castrationresistant prostate cancer (CRPC). Despite newer potent AR-pathway inhibitors, resistance frequently occurs. While co-targeting the AR with adaptive survival pathways is a rational goal, many biologically relevant genes are undruggable with small molecule inhibitors. Gene silencing of non-druggable targets using small-interfering RNA (siRNA) is a promising approach but in vivo delivery remains problematic without a delivery system. We developed a lipid nanoparticle Research.
Introduction
Prostate cancer is the most prevalent cancer in men in the Western world and the second leading cause of cancer deaths among males in Western countries (1) . Androgen receptor (AR) signalling remains the key driver of castration-resistant prostate cancer (CRPC). Potent AR pathway inhibitors like enzalutamide (ENZ) inhibit AR nuclear translocation and transcriptional activity (2, 3) , but despite significant activity, progression to ENZ-resistant (ENZ-R) CRPC frequently occurs. This progression occurs with rising serum PSA levels, thereby implicating AR importance in disease progression. Activation of adaptive survival pathways that support AR signalling is an important mechanism of treatment resistance. The molecular chaperone clusterin (CLU) is induced by AR pathway inhibition and highly expressed in ENZ-R CRPC (4) , and as a mediator of the stress response confers treatment resistance when over-expressed (5) (6) (7) . CLU inhibits stress-induced apoptosis by suppressing p53-activating stress signals (8) , and conformationally altered Bax (6, 8) in addition to enhancing AKT phosphorylation (9) and transactivation of NF-kB (10) and autophagy (11) . In keeping with these cytoprotective mechanisms, CLU inhibition potentiates activity of anticancer therapy in many preclinical models (12) , and is a promising target for novel therapeutics.
While small-interfering RNA (siRNA) offers the promise for potent and specific gene silencing, poor accumulation at sites of disease and intracellular translocation coupled with poor stability, sensitivity to nucleases, immune stimulation and rapid clearance have made its therapeutic application difficult. A delivery system is crucial to the efficient delivery to target tissue in order to overcome these shortcomings. Encapsulation of siRNA using a lipid nanoparticle based delivery system have shown to be crucial in protecting the nucleic acid based drug from nucleases as well as prolonging circulation, reducing immune stimulation and
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Author Manuscript Published OnlineFirst on June 23, 2015; DOI: 10.1158/1078-0432.CCR- improving intracellular uptake (13) . The most clinically advanced delivery of siRNA employs lipid nanoparticles (LNP) and currently there are 6 different siRNA encapsulated in LNP drugs undergoing clinical studies. The most promising study looks at the treatment of transthyretininduced amyloidosis using a second generation cationic lipid (DLin-MC3-DMA) that is well tolerated and potently silences transthyretin (14) . Two siRNA-LNP studies focus in the treatment of hepatic cancers and early indications suggest safe and active treatments (15) .
Propensity of LNP systems to accumulate in the liver has become a major obstacle in the extrahepatic delivery of siRNA-LNP systems. While pre-clinical studies in prostate cancer (16) and immune cells (17) are promising, distant tumour delivery has not been tested in the clinic. In order to mitigate this higher Peg-lipid content is used to improve the pharmacodynamic and biodistribution of LNP systems to the tumor site (18-20).
Antisense oligonucleotides (ASO) offers another approach to selectively target genes.
While ASOs are primarily used to inhibit "undruggable" targets (21, 22), they may also be of use against drug-resistant targets like that AR in ENZ-resistance (ENZ-R) (23). While AR extinction approaches using ASOs (24) or shRNA (25) can reduce AR levels and inhibit tumor growth in CRPC models, they have not been studied in the context of ENZ-R disease nor in combination with siRNA-mediated co-targeting strategies. In this study, we first investigated the efficacy of LNP siRNA tumor delivery in AR negative PC-3 and AR positive ENZ-R LNCaP prostate cancer. Gene silencing was first validated using LNP LUC-siRNA to silence PC3 stably expressing firefly luciferace (PC3M-luc) in vitro followed by successful gene silencing in subcutaneous and metastatic xenograft models. Once in vivo silencing of LUC was demonstrated, we then evaluated combinatory gene silencing of CLU (using LNP siRNA) and AR (using an 7 inhibition in vitro and in vivo.
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Materials and Methods

Cell lines and reagents
LNCaP were kindly provided by Dr. L.W.K.Chung (1992, MD Anderson Cancer Center, Houston, Tx) and ENZ-R MR49F cell lines were generated, and maintained as previously described (4, 26) . PC-3M-luc (C6) cells, stably expressing firefly luciferase protein, were obtained from Caliper Life Sciences (Hopkinton, MA) and were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Invitrogen) with 5% fetal bovine serum (FBS) and 2 mmol/L L-glutamine. Supplemental Table 1 shows source and authentication of cell lines.
Permanent stocks of cells of authenticated or purchased were prepared and were stored in liquid nitrogen until use. Cells were used for experiments within 6 months. Enzalutamide was purchased from Haoyuan Chemexpress Co., Limited (Shanghai, China). LNP-siRNA were prepared employing a microfluidic mixing apparatus as previously described (30, 32) .
Bioluminescence Imaging
PC-3M-luc cells and tumors in mice were imaged using an IVIS200 camera (Caliper Life crystal violet assay as previously described (34) . Each assay was done in triplicate three times.
Western blotting analysis
Total proteins were extracted using RIPA buffer (50mM Tris, pH 7.2, 1% NP-40, 0.1% deoxycholate, 0.1% SDS, 100mM NaCl, Roche complete protease inhibitor cocktail) and subjected to Western blot analysis as described previously (28) . Primary antibodies are shown in Supplementary Materials and Methods.
Quantitative Reverse Transcription-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen Life Technologies, Inc.) as previously reported (27) . Primers (described in Supplemental Table 2 ) were normalized to β-actin levels as an internal standard, and the comparative cycle threshold (Ct) method was used to calculate relative quantification of target mRNAs. Each assay was conducted in triplicate.
In vivo PC-3M-luc Subcutaneous Tumor
Male athymic mice were inoculated subcutaneously with 2 × 10 6 PC-3M-luc cells. Once tumor bioluminescence signals reached approximately 1 × 10 toxicity due to daily dosing, the dosing regimen was modified from previous studies performed by Lee and colleagues where repeat doses administered at 10 mg/kg for 3 consecutive days followed by administration at days 7, 9 and 11 (16) were modified to daily dosing of 7 mg/kg for 5 days. To evaluate LUC expression, mice were then imaged on days 0 (before treatment), 3, 5, and 8 using an IVIS200 Imaging System and then sacrificed on day 8. LUC expression (photons/second) measured at days 3, 5 and 8 were normalized to corresponding animal at day 0 and expressed as relative increase (%). All animal procedures used in this manuscript were approved and carried out according to the guidelines of the Canadian Council on Animal Care and appropriate institutional certification.
In vivo PC-3M-luc Metastasis Model
PC-3M-luc cells (2 × 10 6 ) were injected intravenously into the tail vein of male athymic photons/second, they were randomly assigned to either 5 mg/kg LNP LUC-siRNA or GFP-siRNA as control and i.v. injected through the lateral tail vein daily for 5 days. To evaluate LUC expression, mice were then imaged on days 0 (before treatment), 3, 5, and 8 using an IVIS200 Imaging System and then sacrificed on day 8. LUC expression measured at days 3, 5 and 8 were normalized to corresponding animal at day 0 and expressed as relative increase (%).
In vivo ENZ-R MR49F Treatment
Male athymic mice were castrated and inoculated subcutaneously with 2 × 10 Tumor volume and serum PSA was measured as previously described (27) . Mice were sacrificed on day 21 and tumors were harvested for evaluation by Western blot analyses, mRNA expression by real-time monitoring of qPCR, and immunohistochemistry. Treatment was extended over a three-week period, with 4 daily injections in the first week and 3 daily injections during the second and third weeks
Immunohistochemistry
Immunohistochemistry was performed as previously described previously (27) . All comparisons of staining intensities were made at 200 x magnifications.
Statistical analysis
All in vitro data were assessed using the student t-test. All in vivo data were compared using the Kruskal-Wallis test (JMP version 8). Levels of statistical significance were set at P < 0.05. photons/second respectively). LNP LUC-siRNA exhibited LUC silencing effects in PC-3M-luc xenografts as early as day 3 post initial administration by maintaining LUC expression at baseline levels, while LNP GFP-siRNA treated showed a 143% increase when normalized to day 0 (Fig. 1C ). Significant silencing was achieved at day 8 as the LUC expression was below baseline at 75% while LNP GFP-siRNA treatment showed a 263% increase in LUC expression. The difference between LNP LUC-siRNA and control LNP GFP-siRNA corresponded to approximately 3 fold decrease in LUC expression (Fig. 1C) . As expected, LUC protein in tumors collected from representative PC3M-luc xenografts (n=3 per group) decreased after treatment with LNP LUC-siRNA as opposed to LNP GFP-siRNA treatment (Fig. 1C and D) and transcript levels decreased by 40% as assessed by quantitative real-time PCR (Fig. 1E) . The reduction of luciferase detection was not due to toxicity induced by LNP siRNA treatment as no significant body weight loss was observed (Supplemental 
siRNA while increased LUC expression at 416% when treated with LNP GFP-siRNA corresponding to a substantial 6.5 fold difference in LUC activity (Fig. 2) . (Fig. 3A and B) . LNP CLU-siRNA reduces mRNA expression of CLU dose dependently (Fig. 3C) . Furthermore, LNP CLU-siRNA significantly enhanced ENZ activity and reduced cell viability in a dose dependent manner (Supplemental Fig. S4 ), similar to reports using OGX-011 (4). We next confirmed this synergistic effect of LNP CLU-siRNA with AR knockdown using AR-ASO. LNP CLU-siRNA significantly enhanced AR-ASO activity and reduced cell viability in a dose dependent manner in ENZ-R MR49F (Fig. 3D ) and parental LNCaP cells (Fig. 3E) . In addition, combination of LNP CLU-siRNA with AR-ASO increased caspase-dependent apoptosis, as shown by cleaved PARP and caspase-3 activity in ENZ resistant MR49F (Fig. 3F ) and parental LNCaP cells (Fig.   3G ). Collectively, these data indicate that LNP CLU-siRNA enhances AR-ASO-induced apoptosis in vitro.
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Research. (Fig. 4A) ; serum PSA levels were also significantly lower (**; p<0.01 and *; p<0.05 respectively) (Fig. 4B) . Waterfall plots of the best tumor volume and serum PSA decline per mouse at any time in 2.5 % and 5 % PEG are shown in Fig. 4C-F respectively. LNP CLU-siRNA formulated with 2.5% PEG trended to better tumor volume and serum PSA decline compared to 5% PEG. CLU protein expression in tumors collected from representative MR49F xenografts (n=3 per group) decreased after treatment with LNP CLUsiRNA (Fig. 5A ) compared to LNP LUC-siRNA (control). CLU mRNA levels were significantly decreased after treatment with 2.5% or 5% PEG LNP CLU-siRNA systems compared with LNP LUC-siRNA (**; p<0.01 and *; p<0.05 respectively) (Fig. 5B ). LNP formulated with 2.5% PEG showed enhanced silencing as indicated by reduced levels of CLU protein and mRNA compared to 5% PEG in vivo. As expected, AR silencing is observed in all mice treated with AR ASO in comparison to the Scramble control (Fig. 5C ). Immunohistochemical analysis revealed significantly decreased CLU expression after treatment with 2.5% PEG LNP CLU-siRNA LNP compared with 2.5% PEG LNP LUC-siRNA as control (***; p<0.001) (Fig. 5D, E) . In addition, tumors treated with 2.5% PEG LNP CLU-siRNA had significantly higher apoptosis rates than 2.5% PEG LNP LUC-siRNA as shown by increased TUNEL staining (*; p<0.05) (Fig. 5F ).
Collectively, these results suggest LNP siRNA delivery systems potently silence CLU and induce apoptosis in ENZ-R prostate cancer in vivo. The improved resistance against nuclease-mediated metabolism afforded by Gen 2.5 chemistry results in a significantly improved tissue half-live in vivo and a longer duration of action with a more intermittent dosing schedule. We show that systemic administration of this AR-ASO potently suppressed levels of AR and delayed progression in vivo compared to controls.
In addition to directly targeting the AR in post-AR pathway inhibitor CRPC, defining interactions between the AR and adaptive survival pathways will define mechanisms supporting treatment resistant CRPC and guide new combinatorial strategies that delay progression. As a key mediator of the stress response, CLU is induced by AR pathway inhibition and its overexpression confers treatment resistance in prostate cancer (4) (5) (6) (7) . CLU has been targeted in prostate cancer where the CLU inhibitor OGX-011 (custirsen, OncoGenex Pharmaceuticals) potentiates anticancer therapies in many preclinical models (12) including prostate cancer (4, 27) .
CLU suppression also inhibits epithelial-mesenchymal transition and suppresses prostate cancer with 2.5% PEG was more effective compared to 5% PEG in vivo. This can be attributed to PEG interfering with release of siRNA to the cytosol. Currently, less than 3% of siRNA of total siRNA delivered is detected in the cytosol using LNP systems with C14 Peg-lipid (38) . With additional PEG coating on the LNP surface the PEG can also interfere with intracellular uptake of particles. Although 5% PEG extends circulation time, the activity of the LNP system would be compromised, this can be overcome by the incorporation of targeting moietes (such as DUPA or folate) conjugated to PEG-lipids (39) . Targeting 
